https://scholars.lib.ntu.edu.tw/handle/123456789/582003
標題: | Hepatitis B virus genotypes: Clinical relevance and therapeutic implications | 作者: | Lin C.-L. JIA-HORNG KAO |
關鍵字: | Chronic hepatitis B; Cirrhosis; Genotype; HBV viral mutation; Hepatitis B virus (HBV); Hepatocellular carcinoma; Interferon-based therapy; Nucleos(t)ide analogues | 公開日期: | 2013 | 卷: | 12 | 期: | 2 | 起(迄)頁: | 124-132 | 來源出版物: | Current Hepatitis Reports | 摘要: | At least ten hepatitis B virus (HBV) genotypes (A to J) with distinct geographic distributions have been recognized. HBV genotype is not only predictive of clinical outcome but also implicated in responsiveness to antiviral therapy, especially interferon-based regimens. HBV genotype-specific immunologic and virological pathogenesis may contribute to heterogeneous clinical outcomes in chronic hepatitis B patients. For example, patients with genotypes C and D infection have a lower rate of spontaneous HBeAg seroconversion. In addition, genotype C and D have a higher frequency of basal core promoter A1762T/G1764A mutation than genotype A and B. Genotypes C and D also carry a higher risk of cirrhosis and HCC development than genotype A and B. Therapeutically, genotype A and B patients have a better response to interferon-based therapy than genotypes C and D patients, but the response to nucleos(t)ide analogues is comparable across all HBV genotypes. In conclusion, genotyping of HBV can help practicing physicians identify chronic hepatitis B patients who are at risk of disease progression and optimize anti-viral therapy in clinical practice. ? 2013 Springer Science+Business Media New York. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878752889&doi=10.1007%2fs11901-013-0166-6&partnerID=40&md5=b763f9982e4f5d0f25a6ad428d455ba4 https://scholars.lib.ntu.edu.tw/handle/123456789/582003 |
ISSN: | 1540-3416 | DOI: | 10.1007/s11901-013-0166-6 | SDG/關鍵字: | adefovir dipivoxil; antivirus agent; entecavir; interferon; lamivudine; nucleoside derivative; nucleotide derivative; peginterferon; telbivudine; tenofovir disoproxil; article; cancer risk; drug efficacy; drug response; genetic association; genetic variability; genotype; geographic distribution; hepatitis B; Hepatitis B virus; high risk patient; human; immune response; liver cell carcinoma; low drug dose; molecular epidemiology; nonhuman; outcome assessment; prognosis; recurrent disease; risk assessment; seroconversion; virus genome; virus load; virus replication; virus virulence |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。